Ecopia BioSciences Inc.
TSX : EIA

Ecopia BioSciences Inc.

October 20, 2006 16:30 ET

Management Changes at Ecopia

MONTREAL, QUEBEC--(CCNMatthews - Oct. 20, 2006) - Ecopia BioSciences Inc. (TSX:EIA) announced today a series of management changes. Mr. Gregory L. White, who joined Ecopia in September 2004 to implement and manage the drug development aspects of the Company, has been appointed Vice-President, Operations. In addition to continuing to oversee the development of our lead compound, ECO-4601, Mr. White will play a key role in business development and strategic alliances activities. Dr Jim McAlpine, Vice-President, Chemistry and Discovery, who was instrumental in the discovery and pre-clinical development of Ecopia's New Chemical Entities, including ECO-4601, will assume direct responsibility of the discovery-related activities including the ECO-4601's analog program, which we believe will lead to our second oncology drug candidate. Dr Emmanuel Zazopoulos, Vice-president, Operations, Drug Discoveries has left the Company to take on new challenges.

Ms. Anne-Marie Guertin, Vice-President, Finance will coordinate all corporate and legal matters following Mr. Ywe J. Looper's resignation from his full-time position as Vice-President, Intellectual Property and Legal Affairs. Mr. Looper will continue his collaboration with the Company in a consulting role and all intellectual property activities will be outsourced to contractors and supervised directly by Dr Pierre Falardeau.

About Ecopia

Ecopia is finding novel anticancer therapies using its proprietary platform DECIPHER® technology. The Company's current focus is to move its lead compound, ECO-4601, through the early clinical phases. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting tumor growth in several xenograft models. It acts through a dual action by blocking the RAS pathway as well as by binding to the Peripheral Benzodiazepine Receptor (PBR), a receptor highly expressed in many cancer cells. ECO-4601 represents a new chemical class owned by Ecopia that is now in a Phase l clinical trial. The novel scaffold of this molecule is the basis for multiple lead compounds at the preclinical stage.

The common shares of Ecopia are listed on the TSX (symbol: EIA).

Additional information about the Company can be obtained from Ecopia's website at www.ecopiabio.com.

This press release contains forward-looking statements and should be read in conjunction with the discussion on risks and uncertainties disclosed in the Company's press release dated October 10, 2006 regarding operating highlights and financial results for the third quarter of fiscal year 2006, and the 2005 annual information form, both of which are available on www.sedar.com.

Contact Information